AbbVie's $10.9 billion cash acquisition of Apogee Therapeutics marks an expansion beyond dermatology into the respiratory space. The deal brings a pipeline targeting atopic dermatitis and asthma, areas where AbbVie sees unmet patient needs. Chairman and CEO Robert A. Michael said the acquisition strengthens the company's ability to deliver innovative medicines while creating long-term shareholder value. AbbVie has led the immunology field for more than two decades, and this deal adds clinical-stage assets that complement its existing portfolio rather than replace it

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

June 22, 2026 07:45 ET (11:45 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.